Springboard for Further Up-Listing Towards NASDAQ or NYSE
The stock of the Canadian biotech company Hemostemix (TSXV:HEM; FRA:2VF0) will be tradable for the first time on the regulated US exchange OTCQB under the symbol HMTXF starting today, Thursday, January 23, 2025. Until now, Hemostemix only had a simple OTC stock listing. The company expects the new listing to result in better tradability and higher stock exchange turnover. Also on this Thursday, the company will present at the Sequire Investor Summit in Puerto Rico at 11:00 AM AST local time with the presentation “Welcome to Your Fountain of Youth”.
Hemostemix CEO Thomas Smeenk commented: “The listing on the OTCQB allows US investors to directly participate in their ‘fountain of youth’ and longevity. As management and directors, we have invested $9.1 million USD in Hemostemix’s ‘Your Fountain of Youth’ since 2020. We have done this because our therapy works. Our treatment with stem cells from autologous blood has proven to be clinically relevant, statistically significant, and safe in 498 treatments and seven clinical trials with 318 subjects.”
OTCQB Listing Serves as Springboard for Further Up-Listing Towards NASDAQ or NYSE
The listing on the OTCQB opens doors to a broader pool of investors, including brokers, managed accounts, institutional investors, and others looking for more reliable and transparent opportunities like HMTXF. OTCQB companies are included in financial data systems such as Bloomberg, Reuters, and Yahoo Finance. The OTCQB serves as a springboard for companies aiming to list on higher exchanges like NASDAQ or NYSE. By demonstrating compliance with TSXV and OTCQB standards, Hemostemix is preparing for an up-listing.
Conclusion: The biotech company Hemostemix could become one of the big winners of the “longevity” megatrend. Its stem cell therapy based on autologous blood helps severely ill people by specifically activating the body’s self-healing powers using its own resources. The groundbreaking stem cell therapy ACP-01 sets new standards in regenerative medicine: The treatment has demonstrably saved limbs, healed ulcers, and ended pain. It’s already becoming apparent that the treatment, which is technically simple for both the treating physician and the patient, is not only used by sick people but also by younger clients who want to use the benefits of the therapy prophylactically to maintain their quality of life for as long as possible. Initially, Hemostemix will manually process the submitted blood samples in the laboratory of partner Cytoimmune in Puerto Rico. However, through the planned automation of production in Puerto Rico, Hemostemix aims to make its therapy highly scalable.
Your Fountain of Youth is an international brand owned by Hemostemix. In short, Your Fountain of Youth describes the results of the therapy: the reversal of cardiovascular diseases in the heart, limbs, and brain (vascular dementia) of patients
